GERMANTOWN, Md., June 28 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective...
Single Non-Inferiority Phase III Trial Design Believed to be Acceptable to FDA GERMANTOWN, Md., June 26 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a...
Company Receives FDA Action Date of January 23, 2008 GERMANTOWN, Md., May 22 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on...
Amoxicillin PULSYS NDA Resubmitted in Quarter; $24 Million Raised in Private Equity Placement Following Quarter-end; Company Begins Process of Exploring Strategic Alternatives GERMANTOWN, Md...
Conference Call and Webcast to Follow GERMANTOWN, Md., May 3 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and...
GERMANTOWN, Md., April 23 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective...
GERMANTOWN, Md., April 18 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective...
GERMANTOWN, Md., April 9 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective...
Resubmission of Amoxicillin PULSYS NDA Complete; Company Pursuing Additional Financing and Identifies Cost-cutting Initiatives to Preserve Cash; Company Retains Investment Bank to Explore...
GERMANTOWN, Md., March 23 /PRNewswire/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.